retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity hormone receptor for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide Phase 3: 28.7% Weight

Retatrutide is an investigational GLP-1/GIP/glucagon triple agonist with no MHRA, EMA, or FDA marketing authorisation

10.3390/jcm11133878 71 NauckM

Preferred therapy: Insulin remains the gold standard

Newer medications are designed to activate both GLP-1 and GIP receptors at the same time, which may provide a stronger effect on appetite regulation and metabolic health

Also, tirzepatide acted as a full and equipotent GIPR agonist, while its interaction with GLP-1R suggested partial agonism

Consistency: Regular injections and follow-up appointments with a healthcare provider can improve adherence and increase success rates